B-I's all oral, interferon-free combo regimen meets PhIIb goals in HCV genotype-1 patients
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim said that its interferon-free therapy – combining the company’s investigational direct-acting antiviral compounds - met the goals in treating HCV in genotype-1 patients after a pre-specified interim analysis of the ongoing, 362-patient Phase IIb SOUND-C2 trial. Most significantly, a subgroup of this hard-to-treat population, those with two prevalent types of HCV found across Europe and Asia (genotype-1a CC and -1b), had viral cure rates (SVR12) without interferon in up to 82% of patients after just 28 weeks of treatment.